{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:08:58Z","timestamp":1794647338507,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-56520-7","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T18:29:27Z","timestamp":1738693767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Targeting ceramide transfer protein sensitizes AML to FLT3 inhibitors via a GRP78-ATF6-CHOP axis"],"prefix":"10.1038","volume":"16","author":[{"given":"Xiaofan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4701-3573","authenticated-orcid":false,"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-8888","authenticated-orcid":false,"given":"Hui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"56520_CR1","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1016\/j.molcel.2021.08.031","volume":"81","author":"C Pan","year":"2021","unstructured":"Pan, C., Li, B. & Simon, M. C. Moonlighting functions of metabolic enzymes and metabolites in cancer. Mol. cell 81, 3760\u20133774 (2021).","journal-title":"Mol. cell"},{"key":"56520_CR2","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.devcel.2021.04.013","volume":"56","author":"LA Broadfield","year":"2021","unstructured":"Broadfield, L. A., Pane, A. A., Talebi, A., Swinnen, J. V. & Fendt, S. M. Lipid metabolism in cancer: New perspectives and emerging mechanisms. Developmental cell 56, 1363\u20131393 (2021).","journal-title":"Developmental cell"},{"key":"56520_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrc.2017.96","volume":"18","author":"B Ogretmen","year":"2018","unstructured":"Ogretmen, B. Sphingolipid metabolism in cancer signalling and therapy. Nat. Rev. Cancer 18, 33\u201350 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"56520_CR4","doi-asserted-by":"publisher","first-page":"101050","DOI":"10.1016\/j.plipres.2020.101050","volume":"79","author":"N Sch\u00f6mel","year":"2020","unstructured":"Sch\u00f6mel, N., Geisslinger, G. & Wegner, M. S. Influence of glycosphingolipids on cancer cell energy metabolism. Prog. lipid Res. 79, 101050 (2020).","journal-title":"Prog. lipid Res."},{"key":"56520_CR5","doi-asserted-by":"publisher","first-page":"108005","DOI":"10.1016\/j.pharmthera.2021.108005","volume":"232","author":"D Canals","year":"2022","unstructured":"Canals, D. & Clarke, C. J. Compartmentalization of Sphingolipid metabolism: Implications for signaling and therapy. Pharmacol. Ther. 232, 108005 (2022).","journal-title":"Pharmacol. Ther."},{"key":"56520_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc3398","volume":"13","author":"SA Morad","year":"2013","unstructured":"Morad, S. A. & Cabot, M. C. Ceramide-orchestrated signalling in cancer cells. Nat. Rev. Cancer 13, 51\u201365 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"56520_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1053\/j.gastro.2018.04.037","volume":"155","author":"AP Bai","year":"2018","unstructured":"Bai, A. P. & Guo, Y. Ceramide is a potential activator of immune responses against tumors. Gastroenterology 155, 579\u2013580 (2018).","journal-title":"Gastroenterology"},{"key":"56520_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-021-01581-y","volume":"20","author":"H Tallima","year":"2021","unstructured":"Tallima, H., Azzazy, H. M. E. & El Ridi, R. Cell surface sphingomyelin: Key role in cancer initiation, progression, and immune evasion. Lipids health Dis. 20, 150 (2021).","journal-title":"Lipids health Dis."},{"key":"56520_CR9","doi-asserted-by":"crossref","unstructured":"Haddadi, N., Lin, Y., Simpson, A. M., Nassif, N. T. & McGowan, E. M. \u201cDicing and Splicing\u201d sphingosine kinase and relevance to cancer. Int. J. Mol. Sci. 18, 1891 (2017).","DOI":"10.3390\/ijms18091891"},{"key":"56520_CR10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nature02188","volume":"426","author":"K Hanada","year":"2003","unstructured":"Hanada, K. et al. Molecular machinery for non-vesicular trafficking of ceramide. Nature 426, 803\u2013809 (2003).","journal-title":"Nature"},{"key":"56520_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tcb.2011.09.003","volume":"22","author":"M Maceyka","year":"2012","unstructured":"Maceyka, M., Harikumar, K. B., Milstien, S. & Spiegel, S. Sphingosine-1-phosphate signaling and its role in disease. Trends cell Biol. 22, 50\u201360 (2012).","journal-title":"Trends cell Biol."},{"key":"56520_CR12","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1002\/1873-3468.13511","volume":"593","author":"K Kumagai","year":"2019","unstructured":"Kumagai, K. & Hanada, K. Structure, functions and regulation of CERT, a lipid-transfer protein for the delivery of ceramide at the ER-Golgi membrane contact sites. FEBS Lett. 593, 2366\u20132377 (2019).","journal-title":"FEBS Lett."},{"key":"56520_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccr.2007.04.011","volume":"11","author":"C Swanton","year":"2007","unstructured":"Swanton, C. et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer cell 11, 498\u2013512 (2007).","journal-title":"Cancer cell"},{"key":"56520_CR14","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/path.2998","volume":"226","author":"AJ Lee","year":"2012","unstructured":"Lee, A. J. et al. CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. J. Pathol. 226, 482\u2013494 (2012).","journal-title":"J. Pathol."},{"key":"56520_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4462-y","volume":"18","author":"VE Palau","year":"2018","unstructured":"Palau, V. E. et al. \u03b3-Tocotrienol induces apoptosis in pancreatic cancer cells by upregulation of ceramide synthesis and modulation of sphingolipid transport. BMC cancer 18, 564 (2018).","journal-title":"BMC cancer"},{"key":"56520_CR16","doi-asserted-by":"crossref","unstructured":"Hanada, K., Sakai, S. & Kumagai, K. Natural ligand-mimetic and nonmimetic inhibitors of the ceramide transport protein CERT. Int. J. Mol. Sci. 23, 2098 (2022).","DOI":"10.3390\/ijms23042098"},{"key":"56520_CR17","doi-asserted-by":"publisher","first-page":"43994","DOI":"10.1074\/jbc.M104884200","volume":"276","author":"S Yasuda","year":"2001","unstructured":"Yasuda, S. et al. A novel inhibitor of ceramide trafficking from the endoplasmic reticulum to the site of sphingomyelin synthesis. J. Biol. Chem. 276, 43994\u201344002 (2001).","journal-title":"J. Biol. Chem."},{"key":"56520_CR18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3233\/JAD-161231","volume":"60","author":"SM Crivelli","year":"2017","unstructured":"Crivelli, S. M. et al. Synthesis, radiosynthesis, and preliminary in vitro and in vivo evaluation of the fluorinated ceramide trafficking inhibitor (HPA-12) for brain applications. J. Alzheimer\u2019s. Dis.: JAD 60, 783\u2013794 (2017).","journal-title":"J. Alzheimer\u2019s. Dis.: JAD"},{"key":"56520_CR19","doi-asserted-by":"publisher","first-page":"16682","DOI":"10.1074\/jbc.M800799200","volume":"283","author":"A Charruyer","year":"2008","unstructured":"Charruyer, A. et al. Decreased ceramide transport protein (CERT) function alters sphingomyelin production following UVB irradiation. J. Biol. Chem. 283, 16682\u201316692 (2008).","journal-title":"J. Biol. Chem."},{"key":"56520_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13195-021-00780-0","volume":"13","author":"SM Crivelli","year":"2021","unstructured":"Crivelli, S. M. et al. CERT(L) reduces C16 ceramide, amyloid-\u03b2 levels, and inflammation in a model of Alzheimer\u2019s disease. Alzheimer\u2019s. Res. Ther. 13, 45 (2021).","journal-title":"Alzheimer\u2019s. Res. Ther."},{"key":"56520_CR21","doi-asserted-by":"crossref","unstructured":"Chung, L. H., Liu, D., Liu, X. T. & Qi, Y. Ceramide transfer protein (CERT): An overlooked molecular player in cancer. Int. J. Mol. Sci. 22, 13184 (2021).","DOI":"10.3390\/ijms222413184"},{"key":"56520_CR22","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1182\/blood-2016-04-708750","volume":"128","author":"M Dany","year":"2016","unstructured":"Dany, M. et al. Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. Blood 128, 1944\u20131958 (2016).","journal-title":"Blood"},{"key":"56520_CR23","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1182\/blood.2021013277","volume":"139","author":"AC Lewis","year":"2022","unstructured":"Lewis, A. C. et al. Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia. Blood 139, 3737\u20133751 (2022).","journal-title":"Blood"},{"key":"56520_CR24","doi-asserted-by":"publisher","first-page":"24397","DOI":"10.1074\/jbc.M112.344432","volume":"287","author":"F Hullin-Matsuda","year":"2012","unstructured":"Hullin-Matsuda, F. et al. Limonoid compounds inhibit sphingomyelin biosynthesis by preventing CERT protein-dependent extraction of ceramides from the endoplasmic reticulum. J. Biol. Chem. 287, 24397\u201324411 (2012).","journal-title":"J. Biol. Chem."},{"key":"56520_CR25","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/bloodadvances.2023010535","volume":"8","author":"BB Paudel","year":"2024","unstructured":"Paudel, B. B. et al. Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes. Blood Adv. 8, 1137\u20131142 (2024).","journal-title":"Blood Adv."},{"key":"56520_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/2643-3230.BCD-20-0155","volume":"2","author":"SZ Xie","year":"2021","unstructured":"Xie, S. Z. et al. Sphingosine-1-phosphate receptor 3 potentiates inflammatory programs in normal and leukemia stem cells to promote differentiation. Blood cancer Discov. 2, 32\u201353 (2021).","journal-title":"Blood cancer Discov."},{"key":"56520_CR27","doi-asserted-by":"crossref","unstructured":"F\u00e9ral, K. et al. ER stress and unfolded protein response in Leukemia: Friend, foe, or both? Biomolecules 11, 199 (2021).","DOI":"10.3390\/biom11020199"},{"key":"56520_CR28","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.trecan.2020.05.012","volume":"6","author":"A Khateb","year":"2020","unstructured":"Khateb, A. & Ronai, Z. A. Unfolded protein response in Leukemia: From basic understanding to therapeutic opportunities. Trends cancer 6, 960\u2013973 (2020).","journal-title":"Trends cancer"},{"key":"56520_CR29","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1038\/s41375-024-02321-8","volume":"38","author":"C Philippe","year":"2024","unstructured":"Philippe, C. et al. Pivotal role of the endoplasmic reticulum stress-related XBP1s\/miR-22\/SIRT1 axis in acute myeloid leukemia apoptosis and response to chemotherapy. Leukemia 38, 1764\u20131776 (2024).","journal-title":"Leukemia"},{"key":"56520_CR30","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nature13228","volume":"510","author":"P van Galen","year":"2014","unstructured":"van Galen, P. et al. The unfolded protein response governs integrity of the haematopoietic stem-cell pool during stress. Nature 510, 268\u2013272 (2014).","journal-title":"Nature"},{"key":"56520_CR31","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.celrep.2018.10.021","volume":"25","author":"P van Galen","year":"2018","unstructured":"van Galen, P. et al. Integrated stress response activity marks stem cells in normal hematopoiesis and Leukemia. Cell Rep. 25, 1109\u20131117.e1105 (2018).","journal-title":"Cell Rep."},{"key":"56520_CR32","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.stem.2019.09.008","volume":"25","author":"SZ Xie","year":"2019","unstructured":"Xie, S. Z. et al. Sphingolipid modulation activates proteostasis programs to govern human hematopoietic stem cell self-renewal. Cell Stem Cell 25, 639\u2013653.e637 (2019).","journal-title":"Cell Stem Cell"},{"key":"56520_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/emmm.201201283","volume":"5","author":"SA Saddoughi","year":"2013","unstructured":"Saddoughi, S. A. et al. Sphingosine analogue drug FTY720 targets I2PP2A\/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol. Med. 5, 105\u2013121 (2013).","journal-title":"EMBO Mol. Med."},{"key":"56520_CR34","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1158\/2159-8290.CD-22-0411","volume":"13","author":"M Sabatier","year":"2023","unstructured":"Sabatier, M. et al. C\/EBP\u03b1 confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia. Cancer Discov. 13, 1720\u20131747 (2023).","journal-title":"Cancer Discov."},{"key":"56520_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109076","volume":"35","author":"S Vaena","year":"2021","unstructured":"Vaena, S. et al. Aging-dependent mitochondrial dysfunction mediated by ceramide signaling inhibits antitumor T cell response. Cell Rep. 35, 109076 (2021).","journal-title":"Cell Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56520-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56520-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56520-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T11:25:35Z","timestamp":1741605935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56520-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["56520"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-56520-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"7 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Authors declare the following competing interests: R.P.G. is a consultant to NexImmune Inc. Nanexa Pharma Ascentage Pharm Group and Antengene Biotech LLC, Medical Director of FFF Enterprises Inc.; Partner in AZCA Inc.; Board of Directors of Russian Foundation for Cancer Research Support and Scientific Advisory Board of StemRad Ltd. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1358"}}